Every 10-Q that Spero Therapeuti (SPRO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SPRO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SPRO filings page.
Spero Therapeutics, Inc. reported that for the three months ended June 30, 2026, total revenue was $0, down from $14.2 million a year earlier as prior-period BARDA grant and GSK collaboration revenue wound down. Operating expenses fell to $9.9 million from $16.6 million, but the absence of revenue drove a higher net loss of $9.6 million versus $1.7 million in the prior-year quarter.
For the six months ended June 30, 2026, the company recorded $16.8 million in net loss compared with $15.6 million a year earlier. Cash, cash equivalents and restricted cash were $50.8 million at June 30, 2026, up from $31.2 million a year before, supported by positive operating cash flow of $10.5 million in the first half of 2026.
The business has pivoted from tebipenem pivoxil to immunology, with lead program SP001, a fully humanized Fc-silent IgG1 antibody targeting CD40L, in development for IgG4-related disease. In June 2026, the FDA approved GSK’s NDA resubmission for Utebzi, triggering future milestone and royalty potential under the GSK license. Subsequent to quarter-end, Spero entered a $105.0 million royalty financing with affiliates of HCRx backed by a portion of future GSK payments and licensed SP001 globally (outside Greater China) from Innovent. Management states that existing cash plus royalty financing proceeds are expected to fund operations for at least 12 months from the issuance date.
Spero Therapeutics reported a smaller quarterly loss as it continued shifting its business toward the tebipenem HBr program partnered with GSK. For the three months ended March 31, 2026, total revenue was $0.3 million, down from $5.9 million a year earlier, mainly due to lower collaboration revenue from GSK as performance obligations were completed.
Research and development expense fell to $2.9 million from $13.6 million, and general and administrative expense declined to $4.9 million, reducing the net loss to $7.2 million, or $0.13 per share. Operating cash flow turned positive, providing $15.9 million, largely from collection of GSK collaboration receivables.
The company ended the quarter with $56.1 million in cash and cash equivalents and stockholders’ equity of $52.9 million. Management expects this cash to fund operations for at least 12 months from the financial statement issuance date but anticipates needing additional capital to develop any future product candidates. Spero’s prospects now largely depend on tebipenem HBr, where a Phase 3 trial met its primary endpoint and GSK’s resubmitted NDA has a PDUFA date of June 18, 2026.
Spero Therapeutics’ latest quarterly report shows a narrower loss and a sharper focus on its lead antibiotic candidate tebipenem HBr. For the quarter ended September 30, 2025, total revenue was $5.4 million, down from $13.5 million a year earlier as grant and collaboration revenue declined. Net loss improved to $7.4 million from $17.1 million, helped by lower research and development spending and collaboration milestone receipts.
At September 30, 2025, Spero held $48.6 million in cash and cash equivalents and stockholders’ equity of $26.5 million. Management believes this cash, combined with lower clinical spending after completing the pivotal PIVOT-PO trial, will fund operations for at least 12 months, but additional capital will be needed to carry products through approval and commercialization.
Strategically, Spero has ceased development of SPR206 and SPR720 and is now heavily dependent on tebipenem HBr and its license partnership with GSK. The PIVOT-PO Phase 3 trial in complicated urinary tract infections met its primary endpoint and was stopped early for efficacy, and GSK plans to file with the FDA in the fourth quarter of 2025. Key risks highlighted include continued operating losses, dependence on milestone and grant payments, manufacturing and regulatory uncertainties, stock price volatility, prior Nasdaq listing issues, and an ongoing SEC Wells Notice process related to the company’s 2022 tebipenem disclosures.
Spero Therapeutics (SPRO) reported a strong clinical milestone and narrower losses in the quarter ended June 30, 2025. The pivotal Phase 3 PIVOT-PO trial for tebipenem HBr met its primary endpoint and was stopped early for efficacy after a pre-specified interim analysis of 1,690 patients, and the company has shifted its R&D focus to tebipenem while suspending SPR720 oral development and discontinuing SPR206.
Financially, total revenues were $14.2 million for the quarter and $20.1 million for the six months, driven by related-party collaboration revenue and grant revenue. Net loss improved to $1.7 million for the quarter ($0.03 per share) and $15.6 million for six months ($0.28 per share), compared with larger losses a year earlier. Cash and cash equivalents were $31.2 million at June 30, 2025, down from $52.9 million at year-end, and the company used $21.7 million of cash in operations in the six months. The company received significant upfront and milestone payments from GSK (including a $66.0 million upfront payment) and reports committed BARDA funding of $65.6 million (with $61.1 million recognized to date). The company disclosed an SEC Wells Notice and ongoing cooperation with the staff, and regained Nasdaq bid-price compliance on June 12, 2025.